Medidata dives into Japanese trials; China targets Indian scientists;

> Medidata ($MDSO) is lending its cloud-based technology to a Japanese pharma group, collaborating to calculate the cost of running clinical trials in the country. More

> Chinese research organizations are poaching Indian scientists in hopes of building up their local formulation expertise, according to The Economic Times. News

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.